Update on Phase I Study of IMP761 for Autoimmune Diseases
Filed with ASX · · 2 pages · English
Story so far
Earlier from Immutep
- TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
- TACTI-004 to be discontinued following futility analysis
- Reinstatement to Quotation
- Suspension from Quotation
- Trading Halt
Later from Immutep
- Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
- Immutep receives FDA ODD for Efti in Soft Tissue Sarcoma
- Immutep Receives FDA Orphan Drug Designation for Eftilagimod Alfa in Soft Tissue Sarcoma
- Immutep Announces Abstract Accepted for Presentation at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
- Immutep Receives Nasdaq Notice of Bid Price Deficiency
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep